EUVIMEDEUVIMED entdecken
Open Access

GOLPH3 inhibition overcomes cisplatin resistance by restoring the glutathione/reactive oxygen species balance in the A549 non‑small cell lung cancer cell line

Qiongying Wei, Jinquan Lin, Zhuangbin Lin, Nanding Yu, Yingxiao Wu, Xuexue Tan, Dan Xue

Oncology Reports · 2024

DOI: 10.3892/or.2024.8829 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Reports, 2024. Verfasst von Qiongying Wei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China. Hauptthemen laut MEDLINE: Cisplatin, Drug Resistance, Neoplasm, Carcinoma, Non-Small-Cell Lung, Glutathione. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cisplatin resistance is common in non‑small cell lung cancer (NSCLC); however, the molecular mechanisms remain unclear. The present study aimed to identify a new function of Golgi phosphoprotein 3 (GOLPH3) in NSCLC‑associated cisplatin resistance. Using A549 human NSCLC cells and the cisplatin‑resistant variant, stable cell lines with GOLPH3 knockdown or overexpression were established using lentiviral vectors. Through Cell Counting Kit‑8 and EdU assays, it was revealed that knockdown of GOLPH3 significantly enhanced cisplatin sensitivity in NSCLC cells. Specifically, flow cytometric analysis showed that GOLPH3 knockdown promoted apoptosis and G2‑phase cell cycle arrest in A549 cells. Mechanistically, intracellular reactive oxygen species (ROS) and glutathione (GSH) levels were measured using assay kits, and it was demonstrated that GOLPH3 knockdown decreased intracellular GSH levels, and further attenuated intracellular cisplatin efflux and GSH/ROS imbalance. In addition, tumor‑sphere formation assays verified that GOLPH3 knockdown mitigated the stem cell‑like phenotype of NSCLC cells. In conclusion, the present findings indicated the relevance of GOLPH3 in NSCLC‑associated cisplatin resistance, and thus targeting GOLPH3 may be developed into a combination therapy to overcome cisplatin resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinDrug Resistance, NeoplasmCarcinoma, Non-Small-Cell LungGlutathioneReactive Oxygen SpeciesLung NeoplasmsMembrane ProteinsApoptosisHumansA549 CellsCell ProliferationGene Knockdown TechniquesAntineoplastic AgentsGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Golgi phosphoprotein 3cisplatin resistanceintracellular glutathionenon‑small cell lung cancerreactive oxygen species

Substanzen

CisplatinGOLPH3 protein, humanGlutathioneReactive Oxygen SpeciesMembrane ProteinsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China.
  • Department of Trauma Center and Emergency Surgery, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350005, P.R. China.
  • Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China.

Zitieren

APA

Wei, Q., Lin, J., Lin, Z., Yu, N., Wu, Y., Tan, X., & Xue, D. (2024). GOLPH3 inhibition overcomes cisplatin resistance by restoring the glutathione/reactive oxygen species balance in the A549 non‑small cell lung cancer cell line. Oncology Reports. https://doi.org/10.3892/or.2024.8829

Vancouver

Wei Q, Lin J, Lin Z, Yu N, Wu Y, Tan X, et al. GOLPH3 inhibition overcomes cisplatin resistance by restoring the glutathione/reactive oxygen species balance in the A549 non‑small cell lung cancer cell line. Oncology Reports. 2024. doi:10.3892/or.2024.8829

BibTeX
@article{Wei2024,
  author = {Wei, Qiongying and Lin, Jinquan and Lin, Zhuangbin and Yu, Nanding and Wu, Yingxiao and Tan, Xuexue and Xue, Dan},
  title = {GOLPH3 inhibition overcomes cisplatin resistance by restoring the glutathione/reactive oxygen species balance in the A549 non‑small cell lung cancer cell line},
  journal = {Oncology Reports},
  year = {2024},
  doi = {10.3892/or.2024.8829}
}
Kostenlos starten →